Under the agreement the contract manufacturing organisation (CMO) will produce the API for formulation, ongoing preclinical development and, eventually, Phase I trials.
ImmuneRegen CEO Michael Wilhelm explained that: “Having a relationship with…Bachem eliminates a number of manufacturing-related hurdles, and provides ImmuneRegen with a partner who understands what the U.S. FDA is looking for from peptide manufacturers.”
The compound, which is a peptide analog of the endogenous neurokinin Substance P, is being developed for a range of infectious and pulmonary disease indications, wound healing and cancer.
